Inovio receives FDA accelerated approval for VOCERYQ and raises $80.5 million
Inovio Pharmaceuticals announced that the FDA granted accelerated approval to VOCERYQ, a DNA‑based therapy for recurrent respiratory papillomatosis, on October 30 2026. The company expects to begin shipping the product within about 60 days and to complete a full commercial launch in the first quarter of 2027. To fund the rollout, Inovio completed a public offering that generated net proceeds of $80.5 million.
Why it matters
The offering provides the cash needed to support VOCERYQ’s market entry, which the company says will enable a transition to a commercial‑stage business. The cash balance of $48.4 million and the new capital extend the firm’s runway into late Q4 2027, giving investors a clearer timeline for potential revenue generation.
Key facts
- 1The FDA issued accelerated approval for VOCERYQ on October 30 2026. prnewswire.com
- 2Inovio plans to make the product available to order and ship roughly 60 days after the approval date. prnewswire.com
- 3A full field deployment is targeted for the first quarter of 2027. prnewswire.com
- 4The company raised $80.5 million in net proceeds from a public offering to back the launch. prnewswire.com
- 5For the quarter that ended on September 30 2026, the company recorded a loss of $49.2 million, equating to $0.50 per basic and diluted share. investing.com
- 6Research and development expenses for the quarter were $10.6 million. sec.gov
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.